Research Use Only. The information presented here is for scientific and educational purposes. These compounds are not intended for human consumption, self-administration, or therapeutic use.
Introduction
The term glucagon-like peptide-3 has entered the metabolic research vocabulary through a side door. Unlike glucagon-like peptide-1 and glucagon-like peptide-2, which are named for the positions they occupy in a single precursor protein, there is no endogenous hormone called glucagon-like peptide-3 and no dedicated GLP-3 receptor. The label is shorthand, used informally to describe the next step past single-receptor and dual-receptor incretin research: synthetic peptides characterized for simultaneous agonist activity at three separate metabolic receptors.
This overview explains where that shorthand comes from, what the proglucagon family actually contains, and what triple receptor agonism means at the level of receptor pharmacology. It then places the coded research designation GLP-3 RT within that framework. Everything described here reflects in-vitro assay work and animal-model observations. These materials are supplied for research use only, not for human consumption, and nothing below describes a clinical outcome.
What Does “Glucagon-Like Peptide-3” Actually Refer To?
The naming convention behind GLP-1 and GLP-2 is anatomical rather than functional. Both peptides are cleavage products of proglucagon, the precursor protein encoded by the GCG gene. Tissue-specific processing enzymes cut proglucagon at different sites in pancreatic alpha cells, intestinal L cells, and certain brainstem neurons, releasing a defined set of fragments. GLP-1 and GLP-2 are the first and second glucagon-like sequences to emerge from that precursor, and the numbering stops there. No third glucagon-like fragment exists in the proglucagon sequence.
Searches for glucagon like peptide 3 and glp3 therefore return material about a research category rather than a hormone. In practice the term is applied to engineered peptides that act at three receptors at once: the GLP-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Reviews published through 2025 and 2026 tracing the progression from single-receptor to multi-receptor incretin pharmacology describe exactly this class, though the peer-reviewed literature calls them tri-agonists or triple receptor agonists rather than GLP-3. Understanding that distinction is the first step in reading the research accurately.
The Proglucagon Family and Its Receptors
Because the GLP-3 label borrows its numbering from the proglucagon system, it helps to see the actual contents of that system side by side. The values below reflect commonly reported laboratory attributes and are provided for comparison only.
| Proglucagon-Derived Peptide | Sequence Length | Approx. Molecular Weight | Principal Receptor Studied |
|---|---|---|---|
| Glucagon | 29 amino acids | ~3483 Da | Glucagon receptor (GCGR) |
| GLP-1 (7-36 amide) | 30 amino acids | ~3298 Da | GLP-1 receptor (GLP-1R) |
| GLP-2 | 33 amino acids | ~3922 Da | GLP-2 receptor (GLP-2R) |
| Oxyntomodulin | 37 amino acids | ~4449 Da | GCGR and GLP-1R (dual, native) |
| Glicentin | 69 amino acids | ~8100 Da | No single defined receptor |
| Glucagon-like peptide-3 | Not applicable | Not applicable | No endogenous peptide or receptor |
Oxyntomodulin as the Natural Precedent
One entry in that table matters more than the others for understanding multi-receptor design. Oxyntomodulin is a naturally occurring proglucagon fragment that engages both the glucagon receptor and the GLP-1 receptor, making it an endogenous dual agonist. Its existence supplied the original biological argument for engineering peptides that deliberately recruit more than one receptor. Synthetic scaffolds extend that idea by adding a third arm and tuning relative potency at each target.
The Receptor That Is Not in the Family
The third receptor in triple agonism, GIPR, sits outside the proglucagon system entirely. Glucose-dependent insulinotropic polypeptide is a 42-amino-acid peptide encoded by its own gene and released from intestinal K cells. It is grouped with GLP-1 as an incretin because both are secreted in response to nutrient intake and both signal through class B receptors, but it is not a glucagon-like peptide by sequence origin. Two of the three receptors involved trace to the proglucagon family; one does not.
Triple Receptor Agonism in Preclinical Research
All three receptors under study are class B GPCRs that couple primarily to Gs proteins and raise intracellular cyclic AMP when activated. That shared second messenger is what makes a single peptide scaffold plausible as a multi-receptor ligand, and it is also why potency at each receptor is measured with comparable cAMP accumulation assays in transfected cell lines.
The Three Signaling Arms
GLP-1R is expressed in pancreatic beta cells, the gastrointestinal tract, and regions of the central nervous system, and is investigated in cell models for glucose-dependent insulinotropic signaling. GIPR is found on beta cells and adipocytes, and preclinical work examines whether concurrent GIPR and GLP-1R engagement produces complementary activity on insulin-secretion pathways in rodent and cell models. GCGR is concentrated in hepatocytes, where glucagon signaling is studied in relation to hepatic glucose output, lipid oxidation, and cellular energy expenditure.
Why a Third Arm Is Studied
The mechanistic rationale reported in the preclinical literature is one of counterbalance. Glucagon receptor activity is associated with increased energy expenditure and hepatic lipid handling in animal models, while incretin receptor activity is associated with glucose-dependent insulin signaling. Investigators studying tri-agonist scaffolds examine whether the incretin arms offset the glycemic consequences of glucagon receptor engagement. Work published in 2025 and 2026 in journals including Molecular Metabolism and Peptides continues to dissect the distinct and complementary contributions of GLP-1 and glucagon receptor signaling in diet-induced obese mice, with multiomic analyses pointing to hepatic lipid metabolism as a central readout.
Potency Balance as the Design Variable
A triple agonist is not simply the sum of three activities. Reported in-vitro potency at each receptor is rarely equal, and the ratio between the three is the central parameter in structure-activity work; in-silico mutagenesis approaches published in 2026 have been applied to holding triple-receptor activity while preserving metabolic stability. For laboratory purposes, two peptides sharing the same three-receptor label can behave quite differently in the same assay panel.
GLP-3 RT and Related Coded Research Designations
Rejuven8 lists its metabolic research peptides under coded designations. GLP-3 RT is the designation for the triple-receptor research peptide described above: a 39-amino-acid single-chain peptide on a modified GIP-like backbone, carrying substitutions that stabilize the helix and a fatty-diacid moiety supporting reversible albumin binding in animal pharmacokinetic work. The values below reflect commonly reported laboratory attributes and are provided for comparison only.
| Coded Designation | Receptor Targets | Agonism Class | Sequence Length | Approx. MW |
|---|---|---|---|---|
| GLP-1 SM | GLP-1R | Mono-agonist | 31 aa | ~4114 Da |
| GLP-2 TZ | GLP-1R, GIPR | Dual-agonist | 39 aa | ~4814 Da |
| GLP-3 RT | GLP-1R, GIPR, GCGR | Triple-agonist | 39 aa | ~4731 Da |
| Cagrilintide | Amylin and calcitonin receptors | Amylin analog | 32 aa | ~3752 Da |
Note that the coded designation GLP-2 TZ refers to a dual-receptor research peptide and is not the endogenous intestinal hormone GLP-2 listed in the proglucagon table above. The two share a numeral and nothing else. Alongside these sit the mono-agonist GLP-1 SM and the amylin-analog research peptide Cagrilintide, which is often included in comparative assay panels because it acts through an entirely separate receptor system.
Laboratory Handling and Verification
Multi-receptor peptides of this size arrive as a lyophilized powder and are reconstituted before assay work. Adding 2 mL of bacteriostatic water to a 5 mg vial yields a 2.5 mg/mL stock, from which serial dilutions are prepared for cAMP or binding assays. Solvent chemistry is covered in the bacteriostatic water reconstitution guide and the reconstitution chemistry overview rather than repeated here.
A receptor-potency comparison is only as good as the identity of the material in the vial, so purity and mass confirmation carry particular weight here. Knowing how to read a peptide COA allows the reported sequence length and molecular weight to be checked against lot documentation before an experiment begins. Cold storage and minimized freeze-thaw cycles preserve the lipidated scaffold, as the storage and handling notes describe. Peptides in this family sit alongside their comparators in the full research peptide catalog. Read as a research category rather than a hormone, glucagon-like peptide-3 describes a triple receptor agonist under active preclinical characterization, and nothing more.
Frequently Asked Questions
What is glucagon-like peptide-3?
There is no endogenous hormone called glucagon-like peptide-3. The proglucagon precursor yields glucagon, GLP-1, GLP-2, oxyntomodulin, and glicentin, and the numbering stops at two. In research shorthand, glucagon-like peptide-3 refers to synthetic peptides studied for simultaneous agonist activity at three receptors: GLP-1R, GIPR, and GCGR.
Is there a GLP-3 receptor?
No. No GLP-3 receptor has been identified, because no third glucagon-like peptide exists in the proglucagon sequence. Peptides described as GLP-3 are characterized against three previously known receptors rather than a new one.
What is the difference between glucagon like peptide 3 and a triple agonist?
They describe the same research category using different vocabulary. The peer-reviewed literature uses tri-agonist or triple receptor agonist; the informal glp3 label circulates in general search. The technical term is the more precise one, since it names the receptors rather than implying a hormone.
Which three receptors are involved in triple receptor agonism?
The glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). All three are class B G-protein-coupled receptors that raise intracellular cyclic AMP when activated, which is why a single peptide scaffold can be engineered to engage all three.
What are the molecular attributes of GLP-3 RT?
GLP-3 RT is commonly reported as a 39-amino-acid peptide with an approximate molecular weight near 4731 Da, built on a modified GIP-like backbone with a fatty-diacid moiety supporting albumin binding. These values reflect commonly reported laboratory attributes and are provided for comparison only.
Is GLP-3 RT intended for human use?
No. GLP-3 RT is supplied strictly as a laboratory material for research use only, not for human consumption or self-administration. All available characterization comes from in-vitro assays and animal models.
References and Further Reading
- Processing of the proglucagon precursor and the peptides it yields in pancreatic and intestinal tissue. PubMed: proglucagon processing GLP-1 GLP-2
- Reviews tracing incretin pharmacology from single-receptor to dual and triple receptor agonists. PubMed: incretin dual triple agonist review
- Preclinical characterization of GLP-1, GIP, and glucagon receptor tri-agonist peptides in rodent models. PubMed: GLP-1 GIP glucagon tri-agonist rodent
- Distinct and complementary metabolic effects of GLP-1 and glucagon receptor agonism in diet-induced obese mice. PubMed: GLP-1 glucagon receptor agonism diet-induced obese mice
- Oxyntomodulin as an endogenous dual glucagon and GLP-1 receptor ligand. PubMed: oxyntomodulin dual receptor
- Structure and activation mechanisms of class B G-protein-coupled receptors. PubMed: class B GPCR peptide agonist structure
- Computational design of metabolically stable peptides with triple-hormone-receptor activity. PubMed: peptide design triple hormone receptor agonist
